Daniel Armstrong
This is a likely match — the affiliation was inferred from OpenAlex, ORCID, and web sources but has not been fully confirmed. Treat with appropriate caution.
Role not yet determined Is this you? Add your title
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Daniel Armstrong's research focuses on the discovery of quinazoline-based dual inhibitors targeting RET and Aurora B kinases. This work is aimed at developing potential treatments for non-small cell lung cancer. His recent publication in 2026 highlights his active engagement in this area of study.
Metrics
- Publications: 1
Selected Publications
-
Discovery of quinazoline-based dual RET/Aurora B inhibitors for non-small cell lung cancer (2026)
Collaboration Network
Top Collaborators
- Discovery of quinazoline-based dual RET/Aurora B inhibitors for non-small cell lung cancer
- Discovery of quinazoline-based dual RET/Aurora B inhibitors for non-small cell lung cancer
- Discovery of quinazoline-based dual RET/Aurora B inhibitors for non-small cell lung cancer
- Discovery of quinazoline-based dual RET/Aurora B inhibitors for non-small cell lung cancer
- Discovery of quinazoline-based dual RET/Aurora B inhibitors for non-small cell lung cancer
- Discovery of quinazoline-based dual RET/Aurora B inhibitors for non-small cell lung cancer
- Discovery of quinazoline-based dual RET/Aurora B inhibitors for non-small cell lung cancer
- Discovery of quinazoline-based dual RET/Aurora B inhibitors for non-small cell lung cancer
- Discovery of quinazoline-based dual RET/Aurora B inhibitors for non-small cell lung cancer
- Discovery of quinazoline-based dual RET/Aurora B inhibitors for non-small cell lung cancer
Similar Researchers
Based on overlapping research topics